Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration

Adrienne W. Scott; Susan B. Bressler

doi:10.1097/ICU.0b013e32835fefee

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration

Adrienne W. Scott, Susan B. Bressler

School of Medicine

Research output: Contribution to journal › Review article › peer-review

55 Scopus citations

Abstract

Patients with NVAMD enjoy heretofore unprecedented vision gains when managed with anti-VEGF therapy, and the limited body of evidence to date regarding long-term anti-VEGF treatment shows these vision gains can be maintained through 2 years. Further investigation is needed to explore the effects of long-term anti- VEGF therapy beyond 2 years.

Original language	English (US)
Pages (from-to)	190-196
Number of pages	7
Journal	Current opinion in ophthalmology
Volume	24
Issue number	3
DOIs	https://doi.org/10.1097/ICU.0b013e32835fefee
State	Published - May 2013

Keywords

Aflibercept
Age-Related Macular Degeneration
Bevacizumab
Choroidal Neovascularization
Ranibizumab

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1097/ICU.0b013e32835fefee

Cite this

@article{f9116131cb4f401c9ee286e10a670524,

title = "Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration",

abstract = "Patients with NVAMD enjoy heretofore unprecedented vision gains when managed with anti-VEGF therapy, and the limited body of evidence to date regarding long-term anti-VEGF treatment shows these vision gains can be maintained through 2 years. Further investigation is needed to explore the effects of long-term anti- VEGF therapy beyond 2 years.",

keywords = "Aflibercept, Age-Related Macular Degeneration, Bevacizumab, Choroidal Neovascularization, Ranibizumab",

author = "Scott, {Adrienne W.} and Bressler, {Susan B.}",

year = "2013",

month = may,

doi = "10.1097/ICU.0b013e32835fefee",

language = "English (US)",

volume = "24",

pages = "190--196",

journal = "Current opinion in ophthalmology",

issn = "1040-8738",

publisher = "Lippincott Williams and Wilkins",

number = "3",

}

TY - JOUR

T1 - Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration

AU - Scott, Adrienne W.

AU - Bressler, Susan B.

PY - 2013/5

Y1 - 2013/5

N2 - Patients with NVAMD enjoy heretofore unprecedented vision gains when managed with anti-VEGF therapy, and the limited body of evidence to date regarding long-term anti-VEGF treatment shows these vision gains can be maintained through 2 years. Further investigation is needed to explore the effects of long-term anti- VEGF therapy beyond 2 years.

AB - Patients with NVAMD enjoy heretofore unprecedented vision gains when managed with anti-VEGF therapy, and the limited body of evidence to date regarding long-term anti-VEGF treatment shows these vision gains can be maintained through 2 years. Further investigation is needed to explore the effects of long-term anti- VEGF therapy beyond 2 years.

KW - Aflibercept

KW - Age-Related Macular Degeneration

KW - Bevacizumab

KW - Choroidal Neovascularization

KW - Ranibizumab

UR - http://www.scopus.com/inward/record.url?scp=84876298555&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876298555&partnerID=8YFLogxK

U2 - 10.1097/ICU.0b013e32835fefee

DO - 10.1097/ICU.0b013e32835fefee

M3 - Review article

C2 - 23492430

AN - SCOPUS:84876298555

SN - 1040-8738

VL - 24

SP - 190

EP - 196

JO - Current opinion in ophthalmology

JF - Current opinion in ophthalmology

IS - 3

ER -

Long-term follow-up of vascular endothelial growth factor inhibitor therapy for neovascular age-related macular degeneration

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this